NEW YORK (360Dx) – Proteomics firm Provista Diagnostics has completed a study indicating that its Videssa Breast test could eliminate as many as 45 percent of unnecessary breast biopsies.

The Scottsdale, Arizona-based company is now looking for a partner to lead commercialization of the test and for additional funding to drive the commercialization effort, said Gary Altman, Provista's CEO.

Altman was appointed CEO in February 2018, taking over for David Reese, who headed the firm from 2011 to 2017. Altman was previously chief operating officer at Human Longevity.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.